渤健Biogen (BIIB) 2007年年度报告「NASDAQ」.pdf

1、George HarmonTYSABRI Patient2007 ANNUAL REPORTTransforming Discovery Into Care HighlightsQ1MOVING INTO LATE-STAGE TRIALSBiogen Idec moves three programs into late-stage development,initiating registration trials for lumiliximab in chronic lymphocytic leukemia,galiximab in non-Hodgkins lymphoma and B

2、G-12 for multiple sclerosis.INVESTING IN HEMOPHILIA Biogen Idec acquires Syntonix Pharmaceuticals,adding multiple preclinical programs in hemophilia to the pipeline and investing in the$3 billion market for recombinant factor products.SAFE HARBOR This Annual Report contains forward-looking statement

3、s regarding expected future financial results,the size and growth of the markets for our products,and plans for our product development programs.Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from that which we expect.Important

4、factors that could cause our actual results to differ include our continued dependence on our two principal products,AVONEX and RITUXAN,the uncertainty of success in commercializing other products,including TYSABRI,the occurrence of adverse safety events with our products,the consequences of the nom

5、ination of directors for election to our Board by an activist shareholder,the failure to execute our growth strategy successfully or to compete effectively in our markets,our dependence on collaborations over which we may not always have full control,possible adverse impact of government regulation

6、and changes in the availability of reimbursement for our products,problems with our manufacturing processes and our reliance on third parties,fluctuations in our operating results,our ability to protect our intellectual property rights and the cost of doing so,the risks of doing business internation